cycloSal-2‘,3‘-dideoxy-2‘,3‘-didehydrothymidine Monophosphate (cycloSal-d4TMP):  Synthesis and Antiviral Evaluation of a New d4TMP Delivery System

Journal of Medicinal Chemistry
1998.0

Abstract

The synthesis, hydrolysis, and antiviral evaluation of novel, lipophilic cycloSal-d4TMP derivatives 3a-h of the anti-HIV dideoxynucleoside 2',3'-dideoxy-2',3'-didehydrothymidine (d4T, 1) are reported. This pro-nucleotide concept has been designed to deliver d4TMP (2) by selective chemical hydrolysis. All compounds 3a-h were synthesized using phosphorus(III) chemistry in good yields and in somewhat lower yields using phosphorus(V) chemistry starting from substituted salicyl alcohols 6a-h. The phosphotriesters 3 were obtained without stereochemical preference with respect to the configuration at the phosphorus center as 1:1 diastereomeric mixtures. However, a few of the triesters 3 could be separated into the diastereomers by means of semipreparative HPLC. In a 1-octanol/phosphate buffer mixture, all compounds 3 exhibited 9-100-fold higher lipophilicity as judged from their Pa values as compared to d4T (1). Furthermore, in hydrolysis studies 3 decomposed under mild aqueous basic conditions releasing solely d4TMP (2) and the diols 6 following the designed tandem reaction sequence. A correlation of the electronic properties introduced by the substituents and the half-lives of triesters 3 was observed. Thus, by varying the substituent, the half-lives of 3 could be adjusted over a wide range of compounds still delivering d4TMP (2) selectively. Phosphotriesters 3 exhibited considerable activity against HIV-1 and HIV-2 in wild-type human T-lymphocyte (CEM/O) cells as well as mutant thymidine kinase-deficient (CEM/TK-) cells. Surprisingly, we observed a 3-80-fold difference in antiviral activity between the two diastereomers. Our data clearly prove that the cycloSal-d4TMPs deliver exclusively the nucleotide d4TMP not only under simulated hydrolysis conditions but also under cellular conditions and thus fulfill the thymidine kinase-bypass premise. Therefore, the cycloSal-nucleotide concept is the first reported pro-nucleotide system that delivers the dideoxynucleotide by a pH-driven, chemically activated, tandem reaction without the requirement of an enzymatic contribution.

Knowledge Graph

Similar Paper

cycloSal-2‘,3‘-dideoxy-2‘,3‘-didehydrothymidine Monophosphate (cycloSal-d4TMP):  Synthesis and Antiviral Evaluation of a New d4TMP Delivery System
Journal of Medicinal Chemistry 1998.0
cycloSal-Pronucleotides of 2‘,3‘-Dideoxyadenosine and 2‘,3‘-Dideoxy-2‘,3‘-didehydroadenosine:  Synthesis and Antiviral Evaluation of a Highly Efficient Nucleotide Delivery System
Journal of Medicinal Chemistry 1999.0
cycloSal-Pronucleotides of 2‘-Fluoro-ara- and 2‘-Fluoro-ribo-2‘,3‘- dideoxyadenosine as a Strategy to Bypass a Metabolic Blockade
Journal of Medicinal Chemistry 1999.0
Potential prodrug derivatives of 2',3'-didehydro-2',3'-dideoxynucleosides. Preparations and antiviral activities
Journal of Medicinal Chemistry 1992.0
cycloSal-PMEA and cycloAmb-PMEA:  Potentially New Phosphonate Prodrugs Based on the cycloSal-Pronucleotide Approach
Journal of Medicinal Chemistry 2005.0
Aryl Phosphoramidate Derivatives of d4T Have Improved Anti-HIV Efficacy in Tissue Culture and May Act by the Generation of a Novel Intracellular Metabolite
Journal of Medicinal Chemistry 1996.0
Synthesis and antiviral evaluation of 4′-hydroxymethyl-2′, 3′-dideoxy-3′-thianucleosides and their cyclic monophosphates
Bioorganic & Medicinal Chemistry Letters 1997.0
CycloSal-BVDUMP Pronucleotides:  How to Convert an Antiviral-Inactive Nucleoside Analogue into a Bioactive Compound against EBV
Journal of Medicinal Chemistry 2002.0
Phosphoramidate derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase-deficient cells
Bioorganic & Medicinal Chemistry Letters 1996.0
S-Acyl-2-Thioethyl Aryl Phosphotriester Derivatives of AZT:  Synthesis, Antiviral Activity, and Stability Study
Journal of Medicinal Chemistry 2003.0